The issue of increased risk for leishmaniasis in the era of TNF-α antagonist therapy was recently acknowledged by the European Centre for Disease Prevention and Control [5] and, considering the growing population receiving such treatment, the question undoubtedly deserves further elucidation. This evidence concerns the gene TNF and leishmaniasis.